INOVIO PHARMACEUTICALS, INC. short interest in 2026
In 2026, INOVIO PHARMACEUTICALS, INC.'s disclosed short interest ran from 21.83% of shares outstanding on 15 Jan 2026 to 19.27% on 15 Sep 2026, a change of -2.56 percentage points. The year's high was 23.55% on 29 May 2026 and its low 14.31% on 31 Mar 2026, averaging 20.54% across 17 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 14.79 days on 13 Mar 2026. Full history: INOVIO PHARMACEUTICALS, INC..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2026 in figures
- Start of year
- 21.83% (15 Jan 2026)
- End of year
- 19.27% (15 Sep 2026)
- Change
- -2.56 pp
- High
- 23.55% (29 May 2026)
- Low
- 14.31% (31 Mar 2026)
- Average
- 20.54%
- Highest days to cover
- 14.79 (13 Mar 2026)
- SEC filings marked
- 7
Every report in 2026
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2026 | 21.83% | 5.85 | |
| 30 Jan 2026 | 23.24% | 12.53 | |
| 13 Feb 2026 | 21.31% | 10.09 | |
| 27 Feb 2026 | 20.46% | 14.39 | |
| 13 Mar 2026 | 15.57% | 14.79 | 10-K filed, results (8-K) |
| 31 Mar 2026 | 14.31% | 12.04 | |
| 15 Apr 2026 | 18.48% | 2.71 | |
| 30 Apr 2026 | 20.60% | 9.80 | |
| 15 May 2026 | 23.13% | 3.17 | 10-Q filed, results (8-K) |
| 29 May 2026 | 23.55% | 5.80 | |
| 15 Jun 2026 | 23.45% | 10.78 | |
| 30 Jun 2026 | 21.77% | 10.42 | |
| 15 Jul 2026 | 21.09% | 9.17 | |
| 31 Jul 2026 | 23.22% | 3.13 | results (8-K) |
| 14 Aug 2026 | 19.31% | 3.73 | 10-Q filed, results (8-K) |
| 31 Aug 2026 | 18.62% | 4.36 | |
| 15 Sep 2026 | 19.27% | 6.54 |
See also: INOVIO PHARMACEUTICALS, INC.'s full history · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.